



AP/1642

DOCKET NO: L0461.70099US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Van den Eynde and Boon-Falleur  
Serial No: 09/674,593  
Confirmation No: 9143  
Filed: June 7, 2001  
For: TUMOR ASSOCIATED ANTIGEN ENCODED BY THE REVERSE STRAND OF A NEW UBIQUITOUSLY EXPRESSED GENE

Examiner: Yu, Misook  
Art Unit: 1642

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 26<sup>th</sup> day of March 2004.

  
June Watson

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


Transmitted herewith are the following documents:

- Information Disclosure Statement
- Form PTO-1449 and References Cited
- Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 720-3500, Boston, Massachusetts.

No fee is enclosed. If a fee is necessary, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

By:   
John R. Van Amsterdam, Reg. No. 40,212  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210-2211  
Telephone: (617) 646-8000

Docket No. L0461.70099US00  
Date: March 26, 2004  
xNDD



DOCKET NO: L0461.70099US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant: Van den Eynde and Boon-Falleur  
Serial No: 09/674,593  
Confirmation No: 9143  
Filed: June 7, 2001  
For: TUMOR ASSOCIATED ANTIGEN ENCODED BY THE REVERSE STRAND OF A NEW UBIQUITOUSLY EXPRESSED GENE

Examiner: Yu, Misook  
Art Unit: 1642

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 26th day of March 2004.

  
June Watson

---

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**STATEMENT FILED PURSUANT TO THE DUTY OF DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

**PART I: Compliance with 37 C.F.R. §1.97**

This Information Disclosure Statement has been filed before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. §1.114.

No fee or certification is required.

**PART II: Information Cited**

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

779270.1

The Applicant hereby makes the following additional information of record in the above-identified application.

1. The above-identified U.S. application claims priority to application Serial No. PCT/US99/10424. If the Examiner has not had the benefit of review of the file history of PCT/US99/10424, then he/she is asked to contact the undersigned, who will provide a copy of same.

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

Serial No.: 09/674,593  
Conf. No.: 9143

- 3 -

Art Unit: 1642

An early and favorable action is hereby requested.


Respectfully submitted,

By: John R. Van Amsterdam  
John R. Van Amsterdam, Reg. No. 40,212  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210-2211  
Telephone: (617) 646-8000

Docket No. L0461.70099US00

Date: March 26, 2004

xNDD



FORM PTO-1449/A and B (Modified)				APPLICATION NO.: 09/674,593	DOCKET NO.: L0461.70099US
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				INT'L. FILING DATE: May 13, 1999	CONFIRMATION NO.: 9143
				APPLICANT: Van den Eynde et al	
Sheet	1	of	2	GROUP ART UNIT: 1642	EXAMINER: YU, Misook

### U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYY
		Number	Kind Code		
	A1	5,342,774		Boon et al.	08-30-1994
	A2	5,405,940		Boon et al.	04-11-1995
	A3	5,629,166		van der Bruggen et al.	05-13-1997
	A4	5,620,886		Brichard et al.	04-15-1997
	A5	5,571,711		van der Bruggen et al.	11-05-1996
	A6	5,610,013		Van den Eynde et al.	03-11-1997
	A7	5,587,289		Lurquin et al.	12-24-1996
	A8	5,589,334		Coulie et al.	12-31-1996
	A9	5,487,974		Boon-Falleur	01-30-1996
	A10	5,683,886		van der Bruggen et al.	11-04-1997
	A11	5,648,226		Van den Eynde et al.	07-15-1997
	A12	5,997,870		Coulie et al.	12-07-1999
	A13	5,821,122		Guilloux et al.	10-13-1998

### FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
	B1	WO	92/20356		Ludwig Institute for Cancer Research	26 Nov 1992	
	B2	WO	96/29409		Ludwig Institute for Cancer Research	26 Sep 1996	
	B3	WO	96/10577		Ludwig Institute for Cancer Research	11 Apr 1996	

### OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C1	TRaversari et al., "A Nonapeptide Encoded by Human Gene MAGE-1 is Recognized on HLA-A1 by Cytolytic T Lymphocytes...", <i>J. Exp. Med.</i> 176:1453-1457, 1992	
	C2	VAN DER BRUGGEN et al., "A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma," <i>Science</i> 25: 1643-1647, 1991	
	C3	DE PLAEN et al., "Structure, Chromosomal Localization, and Expression of 12 Genes of the MAGE Family," <i>Immunogenetics</i> 40:360-369, 1994	
	C4	GenBank accession number AA863443	
	C5	GenBank accession number AA004587	
	C6	Brouwennstijn et al., "Renal-Cell Carcinoma-Specific Lysis by Cytotoxic T-Lymphocyte Clones Isolated from Peripheral Blood Lymphocytes..." , <i>Int. J. Cancer</i> 68:177-182, 1996	

MAR 3 1 2004

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**


APPLICATION NO.: 09/674,593

DOCKET NO.: L0461.70099US

INT'L. FILING DATE: May 13, 1999

CONFIRMATION NO.: 9143

APPLICANT: Van den Eynde et al

GROUP ART UNIT: 1642

EXAMINER: YU, Misook

Sheet 2 of 2

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C7	GAUGLER et al., "Human Gene MAGE-3 Codes for an Antigen Recognized on a Melanoma by Autologous Cytolytic T Lymphocytes," <i>Immunogenetics</i> 44:323-330, 1996	
	C8	RAMMENSEE et al., "MHC Ligands and Peptide Motifs: First Listing," <i>Immunogenetics</i> 41:178-228, 1995	
	C9	VAN DEN EYNDE, et al., "A New Antigen Recognized by Cytolytic T Lymphocytes on a Human Kidney Tumor Results from Reverse Strand Transcription; <i>J. Exp. Med.</i> , Rockefeller Univ. Press, Vol. 190, Number 12, December 20, 1999, pgs. 1793-1799	

EXAMINE R DATE CONSIDERED

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_, filed \_\_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).